A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is a common malignant heterogeneous hematopoietic disease with very low average 5-year survival rate due to the refractory feature and high rate of relapse. CD123 is highly expressed on multiple types of AML cells, especially leukemia stem cells, and closely ass...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMC
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0e60652edd234b4d9ef71d32a712ed41 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0e60652edd234b4d9ef71d32a712ed41 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0e60652edd234b4d9ef71d32a712ed412021-11-14T12:05:37ZA novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia10.1186/s13045-021-01206-y1756-8722https://doaj.org/article/0e60652edd234b4d9ef71d32a712ed412021-11-01T00:00:00Zhttps://doi.org/10.1186/s13045-021-01206-yhttps://doaj.org/toc/1756-8722Abstract Acute myeloid leukemia (AML) is a common malignant heterogeneous hematopoietic disease with very low average 5-year survival rate due to the refractory feature and high rate of relapse. CD123 is highly expressed on multiple types of AML cells, especially leukemia stem cells, and closely associated with the poor prognosis of AML. Aiming to meet the urgent demand to targeted therapeutics for the refractory AML patients, herein we synthesize a CD123 antagonistic peptide (PO-6) loaded in nanomicelles (mPO-6), and investigated its therapeutic effect and pharmacokinetics on a lab-established refractory AML mice model (AE & CKITD816V). It is shown that the PO-6 can effectively bind to the CD123+ AML cells and the micellar formulation mPO-6 increases the dissolution stability and the specific binding capacity. When injected intravenously, mPO-6 significantly prolongs the survival of the refractory AML mice by interfering CD123/IL-3 axis, evidenced by the down regulation of phosphorylation of STAT5 and PI3K/AKT and the inhibition of activated NF-κB in the nucleus, as well as by the analysis results of next generation RNA-sequencing (RNA-seq) with the bone marrow of the AML mice. The antagonistic effect leads to the significantly reduction of AML cells infiltration in the bone marrow of the AML mice. In conclusion, mPO-6 could provide a potent antagonistic therapeutic approach for targeted treatment of AML.Shilin XuMeichen ZhangXiaocui FangJie MengHaiyan XingDoudou YanJian LiuYanlian YangTao WenWeiqi ZhangJianxiang WangChen WangHaiyan XuBMCarticleAcute myeloid leukemiaCD123Antagonistic peptideMicelleTargetingDiseases of the blood and blood-forming organsRC633-647.5Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Acute myeloid leukemia CD123 Antagonistic peptide Micelle Targeting Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Acute myeloid leukemia CD123 Antagonistic peptide Micelle Targeting Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shilin Xu Meichen Zhang Xiaocui Fang Jie Meng Haiyan Xing Doudou Yan Jian Liu Yanlian Yang Tao Wen Weiqi Zhang Jianxiang Wang Chen Wang Haiyan Xu A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| description |
Abstract Acute myeloid leukemia (AML) is a common malignant heterogeneous hematopoietic disease with very low average 5-year survival rate due to the refractory feature and high rate of relapse. CD123 is highly expressed on multiple types of AML cells, especially leukemia stem cells, and closely associated with the poor prognosis of AML. Aiming to meet the urgent demand to targeted therapeutics for the refractory AML patients, herein we synthesize a CD123 antagonistic peptide (PO-6) loaded in nanomicelles (mPO-6), and investigated its therapeutic effect and pharmacokinetics on a lab-established refractory AML mice model (AE & CKITD816V). It is shown that the PO-6 can effectively bind to the CD123+ AML cells and the micellar formulation mPO-6 increases the dissolution stability and the specific binding capacity. When injected intravenously, mPO-6 significantly prolongs the survival of the refractory AML mice by interfering CD123/IL-3 axis, evidenced by the down regulation of phosphorylation of STAT5 and PI3K/AKT and the inhibition of activated NF-κB in the nucleus, as well as by the analysis results of next generation RNA-sequencing (RNA-seq) with the bone marrow of the AML mice. The antagonistic effect leads to the significantly reduction of AML cells infiltration in the bone marrow of the AML mice. In conclusion, mPO-6 could provide a potent antagonistic therapeutic approach for targeted treatment of AML. |
| format |
article |
| author |
Shilin Xu Meichen Zhang Xiaocui Fang Jie Meng Haiyan Xing Doudou Yan Jian Liu Yanlian Yang Tao Wen Weiqi Zhang Jianxiang Wang Chen Wang Haiyan Xu |
| author_facet |
Shilin Xu Meichen Zhang Xiaocui Fang Jie Meng Haiyan Xing Doudou Yan Jian Liu Yanlian Yang Tao Wen Weiqi Zhang Jianxiang Wang Chen Wang Haiyan Xu |
| author_sort |
Shilin Xu |
| title |
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| title_short |
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| title_full |
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| title_fullStr |
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| title_full_unstemmed |
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| title_sort |
novel cd123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia |
| publisher |
BMC |
| publishDate |
2021 |
| url |
https://doaj.org/article/0e60652edd234b4d9ef71d32a712ed41 |
| work_keys_str_mv |
AT shilinxu anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT meichenzhang anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT xiaocuifang anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT jiemeng anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT haiyanxing anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT doudouyan anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT jianliu anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT yanlianyang anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT taowen anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT weiqizhang anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT jianxiangwang anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT chenwang anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT haiyanxu anovelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT shilinxu novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT meichenzhang novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT xiaocuifang novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT jiemeng novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT haiyanxing novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT doudouyan novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT jianliu novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT yanlianyang novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT taowen novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT weiqizhang novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT jianxiangwang novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT chenwang novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia AT haiyanxu novelcd123targetedtherapeuticpeptideloadedbymicellardeliverysystemcombatsrefractoryacutemyeloidleukemia |
| _version_ |
1718429447880704000 |